76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Boston Scientific Corp.
Closed
SectorHealthcare
106.1 -0.08
Overview
Share price change
24h
Min
105.98
Max
106.3
Income | 110M 672M |
|---|---|
Sales | 102M 4.7B |
P/E Sector Avg | 75.752 38.156 |
EPS | 0.75 |
Profit margin | 14.411 |
Employees | 53,000 |
EBITDA | 199M 1.2B |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +17.81% upside |
Next Earnings | 22 Oct 2025 |
|---|
Market Cap | -3.1B 154B |
|---|---|
Previous open | 106.18 |
Previous close | 106.1 |
News Sentiment
By Acuity
45%
55%
80 / 375 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
Boston Scientific Corp. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Boston Scientific Corp. Forecast
Price Target
By TipRanks
17.81% upside
12 Months Forecast
Average 125.04 USD 17.81%
High 140 USD
Low 112 USD
Based on 24 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.
Sentiment
By Acuity
80 / 375 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Boston Scientific Corp.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
